Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 688 results
Found 688 results.


Girouard MP, Sax PE, Parker RA, et al. "The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States." Clin. Infect. Dis.. 2016;62(6):784-91.
Freeman ML, Shive CL, Nguyen TP, Younes S-A, Panigrahi S, Lederman MM. "Cytokines and T-Cell Homeostasis in HIV Infection." J. Infect. Dis.. 2016;214 Suppl 2:S51-7.
Chan ES, Landay AL, Brown TT, et al. "Differential CD4+ cell count increase and CD4+ :  CD8+ ratio normalization with maraviroc compared with tenofovir." AIDS. 2016;30(13):2091-7.
Bednar MM, Hauser BM, Zhou S, et al. "Diversity and Tropism of HIV-1 Rebound Virus Populations in Plasma Level After Treatment Discontinuation." J. Infect. Dis.. 2016;214(3):403-7.
Schnitzer ME, Lok JJ, Bosch RJ. "Double robust and efficient estimation of a prognostic model for events in the presence of dependent censoring." Biostatistics. 2016;17(1):165-77.
Jacobson JM, Bosinger SE, Kang M, et al. "The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1." AIDS Res. Hum. Retroviruses. 2016;32(7):636-47.
Weinberg A, Park J-G, Bosch R, et al. "Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women." J. Acquir. Immune Defic. Syndr.. 2016;71(2):137-45.
Bar KJ, Sneller MC, Harrison LJ, et al. "Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption." N. Engl. J. Med.. 2016;375(21):2037-2050.
Moholisa RR, Schomaker M, Kuhn L, et al. "Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children." Pediatr. Infect. Dis. J.. 2016;35(12):e378-e383.
Bedimo R, Kang M, Tebas P, et al. "Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients." AIDS Res. Hum. Retroviruses. 2016;32(4):325-8.
Hosseinipour MC, Bisson GP, Miyahara S, et al. "Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial." Lancet. 2016;387(10024):1198-209.
Luetkemeyer AF, Firnhaber C, Kendall MA, et al. "Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings." Clin. Infect. Dis.. 2016;62(9):1081-8.
Landovitz RJ, Tran TTien T, Cohn SE, et al. "HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States." AIDS Behav. 2016.
Rockwood N, Meintjes G, Chirehwa M, et al. "HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients." Antimicrob. Agents Chemother.. 2016;60(10):6050-9.
Lee SA, Mefford JA, Huang Y, et al. "Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans." AIDS. 2016;30(11):1807-15.
Vardhanabhuti S, Katzenstein D, Bartlett J, Kumarasamy N, Wallis CL. "Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230." Open Forum Infect Dis. 2016;3(3):ofw154.
Shiboski CH, Lee A, Chen H, et al. "Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy." AIDS. 2016;30(10):1573-82.
Matoga MM, Hosseinipour MC, Aga E, et al. "Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings." Antivir. Ther. (Lond.). 2016.
Younes S-A, Freeman ML, Mudd JC, et al. "IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection." J. Clin. Invest.. 2016;126(7):2745-56.
Coiras M, Bermejo M, Descours B, et al. "IL-7 Induces SAMHD1 Phosphorylation in CD4+ T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle." Cell Rep. 2016;14(9):2100-2107.
Mave V, Erlandson KM, Gupte N, et al. "Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults." J. Infect. Dis.. 2016;214(1):65-72.
Petersen T, Lee Y-J, Osinusi A, et al. "Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin." AIDS Res. Hum. Retroviruses. 2016;32(7):660-7.
Robertson K, Jiang H, Evans SR, et al. "International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271." J. Neurovirol.. 2016;22(4):472-8.
Grant PM, Kitch D, McComsey GA, et al. "Long-term body composition changes in antiretroviral-treated HIV-infected individuals." AIDS. 2016;30(18):2805-2813.
Grant PM, Kitch D, McComsey GA, et al. "Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals." J. Infect. Dis.. 2016;214(4):607-11.
Robertson KR, Miyahara S, Lee A, et al. "Neurocognition in maraviroc- compared to tenofovir: a double blind randomized placebo controlled trial ACTG A5303." AIDS. 2016.
Kearney MF, Wiegand A, Shao W, et al. "Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy." J. Virol.. 2016;90(3):1369-76.
Kelesidis T, Jackson N, McComsey GA, et al. "Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection." AIDS. 2016;30(17):2625-2633.
DiRienzo AGregory. "Parsimonious covariate selection with censored outcomes." Biometrics. 2016;72(2):452-62.
Freeman ML, Lederman MM, Gianella S. "Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection." Curr HIV/AIDS Rep. 2016;13(1):10-9.